Zydus Lifesciences gets USFDA OAI status for Jarod facility
Ahmedabad: Zydus Lifesciences has informed in a BSE filing that the United States Food and Drug Administration (USFDA) has determined that the inspection classification of its injectables manufacturing facility located at Jarod, near Vadodara, Gujarat, India as “Official Action Indicated” (OAI).
"We wish to inform that the Company has received a report from the United States Food and Drug Administration (“USFDA”) for the inspection conducted at its injectables manufacturing facility located at Jarod, near Vadodara, Gujarat, India between April 15 and April 23, 2024," Zydus informed.
Headquartered in Ahmedabad, Zydus Lifesciences Limited is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer-related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs.
Read also:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.